Investigating the role of long non-coding RNAs in ER+ breast cancer
Official title: Long non-coding RNA Heterogeneity in ER + Breast Cancer
Funded at University of Virginia · NIH-10884218 · Data updated 2026-11-12
This study is looking at special molecules in breast cancer that has estrogen receptors to see how they might affect the way the cancer grows and responds to treatment, with the hope of finding better, more personalized treatment options for patients like you.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Virginia NIH-funded |
| Lab location | 1 site (Charlottesville, United States) |
| Project start | August 1, 2020 |
| Project end | July 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $112,771 |
| NIH project number | 5K00CA253732-05 |
| Project ID | NIH-10884218 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals diagnosed with estrogen receptor-positive breast cancer.
✕Less likely to help
Patients with other types of breast cancer or those who do not have breast cancer may not receive any benefit from this research.
What this research studies
This research focuses on understanding the diversity of long non-coding RNAs (lncRNAs) in estrogen receptor-positive (ER+) breast cancer. By examining the structure and function of specific lncRNAs, the study aims to uncover their roles in cancer progression and treatment response. Patients may benefit from insights that could lead to more personalized and effective treatment strategies based on the unique lncRNA profiles of their tumors. The research employs advanced molecular biology techniques to analyze tumor samples and identify potential therapeutic targets.
Why it matters
Potential benefit: If successful, this research could lead to more tailored treatment options for patients with ER+ breast cancer, improving outcomes and quality of life.
How similar studies have gone: Previous research has shown promising results in targeting lncRNAs for cancer treatment, indicating potential for success in this area.
Where this research is happening
-
University of Virginia
Charlottesville, United States Active
Researchers
- Principal investigator: Przanowska, Roza Kamila — University of Virginia
- Study coordinator: Przanowska, Roza Kamila
Related research
Other NIH-funded projects on the same topics.
-
ER+ Breast Cancer Bone Metastasis in a Real Body Environment
This grant aims to understand why estrogen receptor alpha–positive breast cancer often spreads to bone and how the bone environment and immune system affect treatment resistance.
-
Targeting RAGE to fight obesity-related ER+ breast cancer and its drug resistance
A scientist team will explore how obesity-related inflammation involving RAGE and estrone interacts with ER+ breast cancer to drive growth and spread, aiming to find strategies to overcome therapy resistance.
-
Understanding estrogen signals in bone to stop ER+ breast cancer spread
This NIH grant aims to uncover how estrogen signals inside bone help ER-positive breast cancer cells grow and spread, with the goal of finding better ways to prevent bone metastasis.
-
Progesterone Receptor Signaling and Dormancy in ER+ Breast Cancer
Researchers are studying how hormone signals in ER+/PR+ breast cancer influence cancer cell dormancy and later recurrence.
-
Heavy Metals and Breast Cancer Treatment Resistance
This project explores how exposure to heavy metals might make ER+ breast cancer harder to treat and how we might overcome this challenge.
-
Turning ER-positive breast cancer into a viral target for immune attack
This project aims to wake up viral-like bits inside ER-positive breast cancer cells so the immune system can spot and attack them.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.